WallStreetZenWallStreetZen

NASDAQ: EWTX
Edgewise Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EWTX

Based on 5 analysts offering 12 month price targets for Edgewise Therapeutics Inc

Min Forecast
$14.00+0.5%
Avg Forecast
$39.80+185.71%
Max Forecast
$51.00+266.12%

Should I buy or sell EWTX stock?

Based on 5 analysts offering ratings for Edgewise Therapeutics Inc.

Buy
Strong Buy
1 analysts 20%
Buy
3 analysts 60%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although EWTX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates EWTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their EWTX stock forecasts and price targets.

EWTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-08
lockedlocked$00.00+00.00%2025-06-30
lockedlocked$00.00+00.00%2025-04-21
lockedlocked$00.00+00.00%2025-04-03
lockedlocked$00.00+00.00%2025-04-02

1 of 1

Forecast return on equity

Is EWTX forecast to generate an efficient return?

Company
-23.11%
Industry
119.29%
Market
-46.52%
EWTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EWTX forecast to generate an efficient return on assets?

Company
-22.19%
Industry
46.9%
EWTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EWTX earnings per share forecast

What is EWTX's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.65
Avg 2 year Forecast
-$2.06
Avg 3 year Forecast
-$2.17

EWTX revenue forecast

What is EWTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$25.0M
Avg 2 year Forecast
$39.9M
Avg 3 year Forecast
$187.2M

EWTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EWTX$13.93$39.80+185.71%Buy
JANX$24.97$58.67+134.95%Buy
SPRY$14.47$30.00+107.33%Buy
BHVN$14.23$44.43+212.22%Strong Buy
VRDN$18.44$35.00+89.80%Buy
View Top Biotech Stocks

Edgewise Therapeutics Stock Forecast FAQ

Is Edgewise Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: EWTX) stock is to Buy EWTX stock.

Out of 5 analysts, 1 (20%) are recommending EWTX as a Strong Buy, 3 (60%) are recommending EWTX as a Buy, 1 (20%) are recommending EWTX as a Hold, 0 (0%) are recommending EWTX as a Sell, and 0 (0%) are recommending EWTX as a Strong Sell.

If you're new to stock investing, here's how to buy Edgewise Therapeutics stock.

What is EWTX's earnings growth forecast for 2025-2027?

(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Edgewise Therapeutics's earnings in 2025 is -$150,704,000.On average, 9 Wall Street analysts forecast EWTX's earnings for 2025 to be -$173,356,897, with the lowest EWTX earnings forecast at -$188,568,817, and the highest EWTX earnings forecast at -$160,125,476. On average, 9 Wall Street analysts forecast EWTX's earnings for 2026 to be -$216,780,398, with the lowest EWTX earnings forecast at -$247,562,414, and the highest EWTX earnings forecast at -$196,996,474.

In 2027, EWTX is forecast to generate -$228,905,689 in earnings, with the lowest earnings forecast at -$321,304,409 and the highest earnings forecast at -$131,682,135.

What is EWTX's revenue growth forecast for 2026-2028?

(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.

Edgewise Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast EWTX's revenue for 2026 to be $2,633,642,700, with the lowest EWTX revenue forecast at $2,633,642,700, and the highest EWTX revenue forecast at $2,633,642,700. On average, 8 Wall Street analysts forecast EWTX's revenue for 2027 to be $4,201,292,181, with the lowest EWTX revenue forecast at $356,068,493, and the highest EWTX revenue forecast at $8,775,297,476.

In 2028, EWTX is forecast to generate $19,721,348,612 in revenue, with the lowest revenue forecast at $9,689,698,222 and the highest revenue forecast at $37,524,141,190.

What is EWTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EWTX) forecast ROA is -22.19%, which is lower than the forecast US Biotechnology industry average of 46.9%.

What is EWTX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year EWTX price target, the average EWTX price target is $39.80, with the highest EWTX stock price forecast at $51.00 and the lowest EWTX stock price forecast at $14.00.

On average, Wall Street analysts predict that Edgewise Therapeutics's share price could reach $39.80 by Aug 8, 2026. The average Edgewise Therapeutics stock price prediction forecasts a potential upside of 185.71% from the current EWTX share price of $13.93.

What is EWTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EWTX) Edgewise Therapeutics's current Earnings Per Share (EPS) is -$1.55. On average, analysts forecast that EWTX's EPS will be -$1.65 for 2025, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$1.52. On average, analysts forecast that EWTX's EPS will be -$2.06 for 2026, with the lowest EPS forecast at -$2.35, and the highest EPS forecast at -$1.87. In 2027, EWTX's EPS is forecast to hit -$2.17 (min: -$3.05, max: -$1.25).

What is EWTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EWTX) forecast ROE is -23.11%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.